OOIR: Observatory of International Research

Papers

(The H4-Index of Hepatology International is 33. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
The safety profile of endoscopic variceal ligation in patients with esophageal varices	132
HBV in pregnancy: time to consider tenofovir alafenamide (TAF)	94
Metabolically healthy obese and MAFLD: does weight status alone matter?	73
Platelets in acute liver failure: an innocent bystander or instigator?	72
Defining the evaluation standards for the cholangiocytic component in cHCC-CCA: a pathology-based perspective	71
Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk	62
N-terminal propeptide of type 3 collagen-based sequential algorithm can identify high-risk steatohepatitis and fibrosis in MAFLD	59
Clathrin light chain A facilitates small extracellular vesicle uptake to promote hepatocellular carcinoma progression	56
Diagnosis of significant liver fibrosis in patients with chronic hepatitis B using a deep learning-based data integration network	51
Commentary on “Comparison of relaxed verses standard cut-offs of rotational thromboelastometry for guiding blood product use before invasive procedures in advanced cirrhosis: a randomized controlled t	49
Midodrine plus propranolol versus propranolol alone in preventing first bleed in patients with cirrhosis and severe ascites: a randomized controlled trial	49
Methodological reflections on vasoconstrictor use in refractory ascites: bridging trial rigor and real-world relevance	47
Response to: “Is laparoscopic hepatectomy superior to laparotomic hepatectomy? The debate continues”	46
Predictive value of soluble PD-1 for HBsAg loss in HbeAg-negative patients with chronic hepatitis B: results from a prospective study	44
p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers	43
Small extracellular vesicles derived from lipotoxic hepatocytes transport FASN to promote hepatic stellate cell activation	42
Antibiotic prophylaxis in upper gastrointestinal bleeding with Child-Pugh A cirrhosis: need for objective infection markers and broader studies	42
Antioxidant, selenium and risk of nonalcoholic fatty liver disease, more than causality	42
Can living donor liver transplantation provide similar outcomes to deceased-donor liver transplantation for hepatocellular carcinoma? A systematic review and meta-analysis	41
Distinct on-treatment HCC risks associated with different decompensation events in HBV patients with cirrhosis	39
Machine learning models in the prediction of 1-year mortality in patients with advanced hepatocellular cancer on immunotherapy: a proof-of-concept study	38
Pure laparoscopic versus open left lateral hepatectomy in pediatric living donor liver transplantation: a review and meta-analysis	38
Impact of CT-relevant skeletal muscle parameters on post-liver transplantation survival in patients with hepatocellular carcinoma	37
Comment on “Comparison of diagnostic criteria for fatty liver disease in assessing cardiac dysfunction: a cross-sectional study”	37
Good outcomes of living donor liver transplant in primary sclerosing cholangitis: an experience from North India	37

Liver stiffness can predict decompensation and need for beta-blockers in compensated cirrhosis: a step beyond Baveno-VI criteria	37
Breaking bottlenecks: the future of hepatocellular carcinoma clinical trials and therapeutic targets	35
The impact of an increased Fibrosis-4 index and the severity of hepatic steatosis on mortality in individuals living with diabetes	35
Comment on “Diabetes mellitus is linked to higher mortality in alcohol‑related acute‑on‑chronic liver failure”	35
Exosome GLUT1 derived from hepatocyte identifies the risk of non-alcoholic steatohepatitis and fibrosis	35
Development of nomograms to predict outcomes for large hepatocellular carcinoma after liver resection	34
APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis	33
The promise of incretin-based pharmacotherapies for metabolic dysfunction-associated fatty liver disease	33
Efficacy and safety of durvalumab rechallenge in advanced hepatocellular carcinoma patients refractory to prior anti-PD-1 therapy	33